|
|
Article: Lunesta Data to Be Presented at American Psychiatric Association Annual Meeting.
- Article from:
- Business Wire
- Article date:
- May 19, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that Phase III/IV clinical data for LUNESTA(TM) brand eszopiclone for the treatment of insomnia will be presented at the American Psychiatric Association (APA) annual meeting in Atlanta.
Posters will be presented on May 25, 2005 in the Georgia World Congress Center, Level 3, Rooms B302-B305 between 12:00 pm and 2:00 pm. The posters are entitled:
--Adjunctive Eszopiclone and Fluoxetine in Major Depressive Disorder (MDD) and Insomnia: Depression Effects
--Adjunctive Eszopiclone With Fluoxetine for MDD and Insomnia: Sleep Effects
--Effect of Eszopiclone on Sleep Parameters ...